Merrimack Pharma Stock Price, News & Analysis

MACK NASDAQ

Company Description

Merrimack Pharma (NASDAQ: MACK) is a publicly traded pharmaceutical preparation manufacturing company in the Pharmaceutical Preparations sector. The company has a market capitalization of $223.7M, ranking #4,399 among all listed U.S. companies by market cap.

MACK stock has declined 100.0% over the past year. Shares last traded at $15.13.

This page provides a comprehensive overview of MACK stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

-100%

Performance 1 year

$223.7M

Market Cap

14.8M

Shares outstanding

Merrimack Pharma (MACK) stock last traded at $15.13. Over the past 12 months, the stock has lost 100.0%. At a market capitalization of $223.7M, MACK is classified as a micro-cap stock with approximately 14.8M shares outstanding.

Latest News

View All

May 10, 2024

-0.13%

Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock

dividends

May 9, 2024

+0.27%

Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution

dividends

April 30, 2024

+1.63%

Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution

March 27, 2024

+0.14%

Merrimack Receives $225 Million Milestone Payment from Ipsen

March 7, 2024

-0.34%

Merrimack Reports Full Year 2023 Financial Results

earnings

February 13, 2024

-2.20%

Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

fda approval

Merrimack Pharma has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include dividends, earnings, fda approval. View all MACK news →

SEC Filings

View All

No SEC filings available for MACK.

Financial Highlights

View Full Financials

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months

MACK Company Profile & Sector Positioning

Merrimack Pharma (MACK) operates in the Pharmaceutical Preparation Manufacturing industry within the broader Pharmaceutical Preparations sector and is listed on the NASDAQ.

Frequently Asked Questions

What is the current stock price of Merrimack Pharma (MACK)?

The current stock price of Merrimack Pharma (MACK) is $15.13 as of March 19, 2025.

What is the market cap of Merrimack Pharma (MACK)?

The market cap of Merrimack Pharma (MACK) is approximately 223.7M. Learn more about what market capitalization means .